Skip to main content

Table 3 Concordance of genotypic and phenotypic resistance in blaCTX-M-harbouring Escherichia coli

From: Molecular detection of blaCTX-M gene to predict phenotypic cephalosporin resistance and clinical outcome of Escherichia coli bloodstream infections in Vietnam

Antibiotic substanceb

blaCTX-M, n = 80a

blaCTX-M-positive ESBL-producers, n = 58a

blaCTX-M-positive non ESBL producers, n = 22a

S

I

R

S

I

R

S

I

R

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

AM

0

–

0

–

80

100

0

–

0

–

58

100

0

–

0

–

22

100

AMC

48

60

9

11.3

23

28.8

40

69

9

15.5

9

15.5

8

36.4

0

–

14

63.6

TZP

64

80

9

11.3

7

8.8

51

87.9

6

10.3

1

1.7

13

59.1

3

13.6

6

27.3

CAZ

35

43.8

1

1.3

44

55

27

46.6

1

1.7

30

51.7

8

36.4

0

–

14

63.6

CTX

11

13.8

0

–

69

86.3

0

–

0

–

58

100

11

50

0

–

11

50

FEPc

37

50

10

13.5

27

36.5

29

55.8

8

15.4

15

28.8

8

36.4

2

9.1

12

54.5

ETP

77

96.3

2

2.5

1

1.3

57

98.3

1

1.7

0

–

20

90.9

1

4.5

1

4.5

IPM

80

100

0

–

0

–

58

100

0

–

0

–

22

100

0

–

0

–

MEM

80

100

0

–

0

–

58

100

0

–

0

–

22

100

0

–

0

–

AN

78

97.5

1

1.3

1

1.3

58

100

0

–

0

–

20

90.9

1

4.5

1

4.5

GM

52

65

3

3.8

25

31.3

39

67.2

1

1.7

18

31

13

59.1

2

9.1

7

31.8

CIP

18

22.5

1

1.3

61

76.3

14

24.1

1

1.7

43

74.1

4

18.2

0

–

18

81.8

  1. AMC: Amoxicillin/Clavulanic acid; TZP: Piperacillin/Tazobactam; ESBL: extended spectrum beta lactamase; CTX: Cefotaxime; CAZ: Ceftazidime; FEP: Cefepime; AN: Amikacin; CIP: Ciprofloxacin; S: susceptible; I: intermediate; R: resistant
  2. aMay not add up to 100% due to rounding errors to 1 decimal place
  3. bInterpretation of resistance according to the clinical breakpoints of CLSI
  4. c6 missing values for cefepime